 |
|
Studies of the Bone Marrow in Immunological GranulocytopeniaFollowing Administration of Salicylazosulfapyridine
ROBERT S. EVANS, M.D.;
WILLIAM P. FORD, Jr., B.S.
AMA Arch Intern Med. 1958;101(2):244-251.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Severe granulocytopenia associated with a decreased resistance to infections was recognized as a new disease syndrome in 1922.1 Nine years later Kracke directed attention to the causal relationship of drugs.2,3 Shortly thereafter, Madison and Squier4 collected evidence that, of all drugs then in use, aminopyrine was most clearly implicated. These authors were also the first to reproduce granulocytopenia by the administration of aminopyrine to patients who had recovered from previous episodes associated with the use of an aminopyrine barbiturate preparation. A dose of 0.3 gm. by mouth was followed within hours by fever, malaise, and a precipitous fall in granulocytes in one patient. The second exhibited only a sharp drop in granulocyte count following the medication. These clinical experiments were repeated and confirmed by others.5,6
Plum's 7 studies of the bone marrow during the administration of aminopyrine to three sensitive patients are of particular interest. He noted a decrease in
. . . [Full Text PDF of this Article]
Author Affiliations
Seattle With the Technical Assistance of Mary Tibbetts, B.A., M.T.
From the Medical Service, Veterans' Administration Hospital, and the Department of Medicine, University of Washington School of Medicine.
Footnotes
Submitted for publication Sept. 30, 1957.
This study was supported by a grant-in-aid from the United States Public Health Service. Project No. A-548 C5.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
|
